RA Capital Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

RA Capital Management’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,264,144	Closed	-$26.7M	–	61
2023 Q1	$26.7M	Hold	4,264,144	–	–	0.6%	43
2022 Q4	$26M	Hold	4,264,144	–	–	0.53%	42
2022 Q3	$51M	Hold	4,264,144	–	–	1.09%	32
2022 Q2	$53.8M	Hold	4,264,144	–	–	1.43%	22
2022 Q1	$48M	Buy	4,264,144 +671,092	+19%	+$7.39M	1.05%	30
2021 Q4	$63.7M	Hold	3,593,052	–	–	1.12%	26
2021 Q3	$82.7M	Hold	3,593,052	–	–	1.15%	28
2021 Q2	$83.6M	Hold	3,593,052	–	–	1.34%	22
2021 Q1	$112M	Hold	3,593,052	–	–	1.69%	16
2020 Q4	$143M	Buy	+3,593,052	New	+$144M	2%	10

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RA Capital Management's KNTE Position: Q2 2023 in Review

RA Capital Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2023, closing a stake of 4,264,144 shares — an estimated $26.7M sold.

RA Capital Management first reported a position in KNTE in Q4 2020 and held it in 10 quarters. The position peaked at $143M in Q4 2020. 72 funds tracked by Wall St. Rank hold KNTE as of Q2 2023.

RA Capital Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
RA Capital Management sold 4,264,144 Kinnate Biopharma Inc. Common Stock shares in Q2 2023, an estimated $26.7M.
RA Capital Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 10 quarters.
RA Capital Management's Kinnate Biopharma Inc. Common Stock position peaked at $143M in Q4 2020.
72 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2023.

Based on RA Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.